The push into biologics addresses rising domestic rates of diabetes and cancer while pursuing broader economic objectives:
-
Reducing Import Dependency: Enhancing domestic production to decrease reliance on foreign medical supplies.
-
Global Supply Chain: Strengthening India’s role and competitiveness in the international biologics supply chain.
-
Regulatory Efficiency: Attracting specialized technical experts to streamline the evaluation process, aligning India’s drug approval timelines with global standards.
Compared to the 2017 National Biopharma Mission (NBM), which had a budget of $166 million, the SHAKTI project represents a major escalation in funding and ambition, positioning India to compete more aggressively in the global high-tech pharmaceutical arena.